文献速递生殖医学

富血小板血浆是否成为失控的附加治疗?临床医生如何维护患者利益

Platelet-rich plasma another add-on treatment getting out of hand? How can clinicians preserve the best interest of their patients?
PubMed 文献 · Hum Reprod · 2019-01-01

本文讨论IVF中附加治疗的滥用问题,指出富血小板血浆(PRP)用于卵巢储备减退、种植失败和薄型子宫内膜缺乏充分证据,仅有小型前后对照研究且终点临床相关性低。作者呼吁在广泛开展PRP前应极度谨慎,等待设计良好的研究结果。

要点

  • IVF附加治疗广泛应用但缺乏充分有效性证据,且可能昂贵并伴未知风险。
  • PRP用于卵巢储备减退、种植失败和薄型子宫内膜仅有小型前后对照研究,终点临床相关性低。
  • PRP尚未经过严格临床试验,应极度谨慎并在广泛开展前等待设计良好的研究结果。

核心结论

  • PRP作为IVF附加治疗基于生物学合理性和理论假设而流行,但缺乏严格临床试验证据,应极度谨慎并等待设计良好的研究结果。

研究设计与样本

  • 原文为评论/观点文章,未报告系统检索范围或研究方法。

主要发现

  • PRP用于卵巢储备减退、种植失败和薄型子宫内膜的证据仅来自小型且多为前后对照研究,终点临床相关性低。
  • PRP尚未经过严格临床试验。

关键数值与推荐

  • 原文未报告具体数值或推荐条款。

临床怎么用

  • 原文建议在广泛实施PRP前应极度谨慎,并等待设计良好的研究结果。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Add-on treatments in IVF are utilized to a great extent but without sufficient evidence showing their effectiveness. Since the offered treatments are usually costly and may be associated with yet unknown risks, this practice is not in the best interest of couples that may go to great lengths to conceive and have an offspring carrying their own genetic make-up. A recent addition to this armamentarium is the administration of platelet-rich plasma (PRP) in women with diminished ovarian reserve, implantation failures, and a thin endometrium. The only evidence for PRP comes from small scale and mostly before and after studies with clinically irrelevant end points. PRP has not been subjected to a rigorous clinical trial. It is a typical example of an add-on gaining widespread popularity based on biological plausibility and mind-bending theoretical presumptions. We should be extremely cautious prior to implementing PRP on a widescale and await the results of well-designed studies.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Urman B, Boza A, Balaban B, et al. Platelet-rich plasma another add-on treatment getting out of hand? How can clinicians preserve the best interest of their patients? Hum Reprod. 2019. PMID: 31725883. doi:10.1093/humrep/dez190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。